Recent Press Releases
March 12, 2026
NervGen announced it has elected to voluntarily delist its common shares from TSX Venture Exchange (“TSXV”), effective at the close of markets on March 16, 2026. The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN.”
March 04, 2026
NervGen appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs.
February 18, 2026
NervGen announced that the Company is scheduled to participate at multiple upcoming investor conferences.
Phase 1b/2a CONNECT SCI Study for
Individuals with Spinal Cord Injury
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
Stay Connected
Subscribe to our mailing list to stay up to date
